IGF-1 LR3 has never gone through any pharmaceutical approval process anywhere in the world. That is a different status from being a specifically "controlled" or "scheduled" substance — many unregulated research chemicals, including IGF-1 LR3, exist in a middle category: not approved for human use, but also not named individually on most controlled-substance schedules.
This distinction is important but easy to misread. "Not scheduled" does not mean "legal to sell as a consumer wellness product" — it means the substance has simply never been reviewed or approved through the pathway that would make it a legitimate pharmaceutical.
In the UAE, IGF-1 LR3 falls into the same general "unscheduled research chemical" category that applies to several other research peptides. It is not approved by the relevant UAE health authorities as a therapeutic product, and there is no established prescription pathway for it, the way there is for regulated pharmaceuticals like HGH.
This general status does not translate into an offer or invitation to purchase. REVIVE LAB UAE does not sell IGF-1 LR3 regardless of its regulatory classification.
Most other jurisdictions treat IGF-1 LR3 similarly: unapproved for human use, generally not specifically scheduled as a controlled substance, though this varies and can change over time as individual countries update their frameworks around performance-enhancing substances and research chemicals more broadly.
Because regulatory frameworks evolve, and because enforcement practices differ meaningfully even where the underlying legal classification is similar, general informational content like this article should never substitute for checking current rules with the relevant authority in any specific country.
It is worth separating two different questions: what category a compound falls into under a given country's law, and whether any particular supplier chooses to stock it. A compound sharing an "unscheduled" classification with catalog items like BPC-157 does not mean every supplier treats them identically — REVIVE LAB UAE has made a deliberate decision to source, test, and document a specific, fixed set of research peptides, and IGF-1 LR3 is not part of that set regardless of its regulatory category.
Buyers researching any compound's legal status should not read shared regulatory categories as implying anything about a specific supplier's catalog or practices.
For UAE-based researchers, the practical takeaway is straightforward: IGF-1 LR3 is not an approved pharmaceutical, is not part of REVIVE LAB UAE's catalog, and cannot be purchased from this site under any circumstances, regardless of its general regulatory category.
This article is general regulatory information, not legal advice. Anyone with specific compliance questions should consult qualified legal counsel or the relevant regulatory authority directly.